尹珍珍, 王优优, 张希梅, 王凤明, 赵路军, 王平, 王佩国, 袁智勇. 不同诱导化疗方案联合放疗治疗鼻咽癌疗效分析[J]. 中国肿瘤临床, 2018, 45(4): 179-184. DOI: 10.3969/j.issn.1000-8179.2018.04.235
引用本文: 尹珍珍, 王优优, 张希梅, 王凤明, 赵路军, 王平, 王佩国, 袁智勇. 不同诱导化疗方案联合放疗治疗鼻咽癌疗效分析[J]. 中国肿瘤临床, 2018, 45(4): 179-184. DOI: 10.3969/j.issn.1000-8179.2018.04.235
shu
Yin Zhenzhen, Wang Youyou, Zhang Ximei, Wang Fengming, Zhao Lujun, Wang Ping, Wang Peiguo, Yuan Zhiyong. Treatment outcomes of different induction chemotherapy regimens combined with intensity-modulated radiotherapy in nasopharyngeal carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 45(4): 179-184. DOI: 10.3969/j.issn.1000-8179.2018.04.235
Citation: Yin Zhenzhen, Wang Youyou, Zhang Ximei, Wang Fengming, Zhao Lujun, Wang Ping, Wang Peiguo, Yuan Zhiyong. Treatment outcomes of different induction chemotherapy regimens combined with intensity-modulated radiotherapy in nasopharyngeal carcinoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 45(4): 179-184. DOI: 10.3969/j.issn.1000-8179.2018.04.235
shu

不同诱导化疗方案联合放疗治疗鼻咽癌疗效分析

Treatment outcomes of different induction chemotherapy regimens combined with intensity-modulated radiotherapy in nasopharyngeal carcinoma

    摘要
  • 摘要:
      目的  分析诱导化疗后行调强放疗的鼻咽癌患者，对比不同诱导化疗方案的治疗疗效。
      方法  回顾性分析2012年1月至2014年6月天津医科大学肿瘤医院初治170例Ⅱ~Ⅳb期鼻咽癌患者临床资料，其中男性126例，女性44例；Ⅱ期27例，Ⅲ期105例，Ⅳa~b期38例。
      结果  全组中位随访时间34个月。3年总生存率、局部区域控制率、无病生存率和无远处转移生存率分别为82.8%、91.5%、76.7%和69.1%。多因素分析发现，含紫杉醇+顺铂的诱导化疗方案较顺铂+5-氟尿嘧啶疾病进展（HR：1.820，95%CI：1.013~3.271，P=0.045）及远处转移风险（HR：2.240，95%CI：1.017~4.090，P=0.045）显著降低。
      结论  含紫杉醇+顺铂的诱导化疗方案较顺铂+5-氟尿嘧啶方案显著延长鼻咽癌患者无病生存率和无远处转移生存率。

     

    Abstract:
      Objective  The role of induction chemotherapy (IC) and preferred regimens is not very clear in non-endemic nasopharyngeal carcinoma (NPC) in northern China.
      Methods  A total of 170 pathologically proven locoregional advanced NPCs between January 2012 and December 2014 were included in this analysis. One hundred and twenty-six were men and 44 patients were women. According to the American Joint Committee on Cancer (AJCC) 7th stage system, 48 patients were T1-2 and 77 patients were T3-4; 48 patients were N0-1 and 122 patients were N2-3; 27 patients were stage Ⅱ, 105 patients were stage Ⅲ, and 38 patients were stage IVa-b.
      Results  The median follow-up time was 34 months. The 3-year overall survival (OS), locoregional failure-free survival (LRFS), distant metastasis-free survival (DMFS), and disease-free survival (DFS) were 82.8%, 91.5%, 76.7%, and 69.1%, respectively. Multivariate analyses showed that IC with TPF (docetaxel, carboplatin, and fluorouracil) or TP (docetaxel and cisplatin) presented superior DFS and DMFS compared with PF (cisplatin+5-FU) DFS-hazard ratio (HR): 1.820, 95% confidence interval (CI): 1.013-3.271, P=0.045; DMFS-HR: 2.240, 95% CI: 1.017-4.090, P=0.045.
      Conclusions  The IC regimens appeared to affect patients' outcomes, and TP-containing IC regimens conferred better DFS and DMFS than PF regimens.

     

    • HTML全文
    • 参考文献(24)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回